A groundbreaking study has provided the strongest evidence yet that thyroid autoimmune diseases like Hashimoto's and Graves' disease are driven by DNA mutations that accumulate in immune cells over a person's lifetime, rather than being purely inherited. Using ultra-accurate DNA sequencing, researchers from the Wellcome Sanger Institute and Cambridge University found that B cells (a type of immune cell) develop mutations that disable the natural "brakes" on the immune system, allowing it to mistakenly attack the thyroid gland .

What Are Somatic Mutations and How Do They Cause Thyroid Disease?

Somatic mutations are DNA changes that occur in our cells over time and are not inherited from parents. Scientists have speculated since the 1950s that these mutations might cause autoimmune diseases, but they lacked the technology to prove it until now. The research team used a cutting-edge DNA sequencing method called NanoSeq, which can detect rare mutations invisible to traditional sequencing, to examine immune cells from patients with Hashimoto's and Graves' disease .

What they found was striking: many B cells in each patient had accumulated multiple mutations in key genes that normally act as "immune checkpoints," controlling whether the immune system attacks or tolerates the body's own tissues. Two critical genes, TNFRSF14 and CD274 (also called PDL1), were frequently inactivated in multiple clones of mutated B cells. Some B cells had acquired as many as six driver mutations over many years, silently building up changes in DNA before symptoms appeared .

Why Does This Discovery Matter for Thyroid Patients?

Currently, autoimmune thyroid diseases are treated by broadly suppressing the entire immune system with medications. This approach can leave patients vulnerable to infections and other complications. The new findings suggest a fundamentally different approach: precision medicine that targets only the specific mutated cell clones causing the problem, rather than shutting down the entire immune system .

"Autoimmune diseases are currently treated by broadly suppressing the immune system, which can leave patients vulnerable to infections as well as a long list of other complications. If these findings are confirmed, they could eventually enable more precise diagnoses and treatments leading to better patient outcomes," stated Dr. Pantelis Nicola, co-first author formerly of the Wellcome PhD Programme for Clinicians in Cambridge and currently a NIHR clinical lecturer at The Christie in Manchester.

Dr. Pantelis Nicola, NIHR Clinical Lecturer at The Christie in Manchester

The study focused specifically on Hashimoto's thyroiditis and Graves' disease, the two leading causes of thyroid dysfunction in the population. However, researchers are already seeing similar mutation patterns in other autoimmune conditions, suggesting this mechanism may be far more widespread than previously understood .

How Does This Research Change Our Understanding of Autoimmune Disease?

For decades, autoimmune diseases have been viewed as primarily genetic or inherited conditions. This research reveals a different picture: a "hidden world" of evolution happening within the immune system itself, where mutations accumulate over time and gradually disable the safeguards that prevent the immune system from attacking the body's own tissues. This process mirrors the early stages of cancer development, but instead of cells multiplying uncontrollably, immune cells develop mutations that remove their ability to distinguish between foreign invaders and healthy body tissues .

The implications are significant. Autoimmune diseases affect 5 to 10 percent of the global population, making this a high-priority area for new diagnostic and treatment approaches. The research team emphasized that this discovery validates a theory first proposed in the 1950s but could never be tested until modern DNA sequencing technology became available .

"Our study suggests that somatic mutations in immune cells may play an important role in autoimmune disease, an idea first proposed in the 1950s that we have lacked the techniques to investigate. Now that we have NanoSeq, which we developed in the last few years, we can study somatic mutations with ultra-high accuracy and explore their contribution to autoimmune diseases, not just cancer," explained Dr. Andrew Lawson, co-first author at the Wellcome Sanger Institute.

Dr. Andrew Lawson, Co-First Author at the Wellcome Sanger Institute

What Are the Next Steps in Translating This Discovery to Patient Care?

While the findings are groundbreaking, researchers acknowledge that further work is needed. The current evidence shows that these mutations are present in patients with thyroid autoimmune disease, but scientists must confirm whether the mutations are the root cause of disease or whether they contribute to its progression over time. Additionally, the preliminary findings in other autoimmune conditions require more investigation before broader conclusions can be drawn .

The research opens several potential avenues for future development:

• Precision Diagnostics: New tests could identify which specific mutated cell clones are driving a patient's thyroid disease, allowing doctors to tailor treatment to the individual's unique immune profile.
• Targeted Therapies: Instead of suppressing the entire immune system, future treatments could target only the mutated B cells responsible for attacking the thyroid, reducing side effects and infection risk.
• Early Detection: Understanding that mutations accumulate silently over years before symptoms appear could enable earlier intervention and prevention strategies.
• Broader Applications: Since similar mutation patterns are emerging in other autoimmune conditions, this approach may eventually apply to rheumatoid arthritis, multiple sclerosis, lupus, type 1 diabetes, and other autoimmune diseases.

The study was published in the journal Nature on April 14, 2026, and involved researchers from the Wellcome Sanger Institute, Cambridge University Hospitals NHS Foundation Trust, the University of Cambridge, and collaborating institutions. The findings represent what some experts are calling a paradigm shift in how we understand and approach autoimmune disease treatment .